2011 Breast Cancer Symposium
Expert Point of View: No Value for Axillary Dissection in Patients with Breast Cancer and Occult Nodal Metastases
Two breast cancer studies presented at the 2011 Breast Cancer Symposium—NSABP B‑32 and ACOSOG Z11—suggest that aggressive approaches to surgically remove occult metastases are not necessary. Armando E...
No Value for Axillary Dissection in Patients with Breast Cancer and Occult Nodal Metastases
In a subanalysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 study, nearly 16% of clinically node-negative patients were found to have occult metastases upon more detailed ...
Studies Validate Safety of Breast-conserving Surgery in Young Patients with Breast Cancer
Young age is not a reason, in itself, to recommend mastectomy for early breast cancer in women aged 40 and under, according to two studies presented at the 2011 Breast Cancer Symposium in San Francisc...
Important Briefs from the 2011 Breast Cancer Symposium
The 2011 Breast Cancer Symposium was recently held in San Francisco, bringing together a multidisciplinary group of specialists and sponsored by ASCO, the American Society for Radiation Oncology, the ...
Novel HDAC Inhibitor May Restore Estrogen Sensitivity in Breast Cancer
The addition of the investigational histone deacetylase (HDAC) inhibitor entinostat significantly delayed breast cancer progression and showed a trend for a survival benefit in the phase II ENCORE 301...
Single-agent Lapatinib Arm Discontinued in ALTTO
The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study, which is evaluating various anti-HER2 therapy approaches in breast cancer, has discontinued the single-agent lapatinib (...
Neoadjuvant Chemotherapy or Surgery First: Outcome Not Affected
Chemotherapy can be delivered before breast-conserving therapy or after surgery, without influencing long-term local-regional recurrence, a large study from The University of Texas MD Anderson Cancer ...
Estrogen for Vulvovaginal Atrophy in Breast Cancer: Debate Continues
Vulvovaginal atrophy is a concern for the majority of patients with breast cancer, not only because of its physical and psychosexual consequences, but because the optimal treatment—estrogen replacemen...
Cathy Eng, MD, on Anal Squamous Cell Cancer: Management Strategies
Michael J. Overman, MD, and François Quenet, MD, on Colorectal Cancer: Results From the PRODIGE 7 Trial
Douglas W. Blayney, MD, on Quality Care: Better, Safer, Cheaper
Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial
Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial
